Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04502706 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision to discontinue development of this molecule

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG: GS-0189
DRUG: Rituximab

Sponsor

Gilead Sciences